Abstract
The presently ongoing pandemic of human SARS‐CoV‐2 infections (COVID‐19) presents an enormous challenge in surveillance, vaccine and antiviral drug development. Here we report the synthesis of new bioactive quinoline‐morpholine hybrid compounds and their virological evaluation, which proves pronounced cell culture‐based inhibitory profile against SARS‐CoV‐2. Thus, selected quinoline compounds may suggest specific hit‐to‐lead development.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
